245 related articles for article (PubMed ID: 29659887)
21. Metformin treatment may be associated with decreased levels of NT-proBNP in patients with type 2 diabetes.
Rosiak M; Postula M; Kaplon-Cieslicka A; Trzepla E; Czlonkowski A; Filipiak KJ; Opolski G
Adv Med Sci; 2013; 58(2):362-8. PubMed ID: 24327531
[TBL] [Abstract][Full Text] [Related]
22. Identification of potential outcome benefit from ACE inhibition after acute coronary syndrome: a biomarker approach using N-terminal proBNP.
Squire I; Quinn P; Narayan H; Khan S; Dhillon O; Ng K; Kelly D; Davies J; Ng L
Heart; 2010 Jun; 96(11):831-7. PubMed ID: 20478862
[TBL] [Abstract][Full Text] [Related]
23. N-terminal pro-B-type natriuretic peptide is inversely associated with metabolic syndrome in hypertensive patients.
Chang HR; Hsieh JC; Hsu BG; Wang LY; Yu-Chih Chen M; Wang JH
Am J Med Sci; 2014 Sep; 348(3):210-4. PubMed ID: 24736765
[TBL] [Abstract][Full Text] [Related]
24. Improvement in insulin resistance is greater when infliximab is added to methotrexate during intensive treatment of early rheumatoid arthritis-results from the IDEA study.
Bissell LA; Hensor EM; Kozera L; Mackie SL; Burska AN; Nam JL; Keen H; Villeneuve E; Donica H; Buch MH; Conaghan PG; Andrews J; Emery P; Morgan AW
Rheumatology (Oxford); 2016 Dec; 55(12):2181-2190. PubMed ID: 27638812
[TBL] [Abstract][Full Text] [Related]
25. Insulin resistance is associated with increased concentrations of NT-proBNP in rheumatoid arthritis: IL-6 as a potential mediator.
Bradham WS; Ormseth MJ; Oeser A; Solus JF; Gebretsadik T; Shintani A; Stein CM
Inflammation; 2014 Jun; 37(3):801-8. PubMed ID: 24402421
[TBL] [Abstract][Full Text] [Related]
26. Cardiovascular safety of metformin and sulfonylureas in patients with different cardiac risk profiles.
Wurm R; Resl M; Neuhold S; Prager R; Brath H; Francesconi C; Vila G; Strunk G; Clodi M; Luger A; Pacher R; Hülsmann M
Heart; 2016 Oct; 102(19):1544-51. PubMed ID: 27226327
[TBL] [Abstract][Full Text] [Related]
27. Insulin therapy in patients with type 2 diabetes and high insulin resistance is associated with increased risk of complications and mortality.
Mendez CE; Walker RJ; Eiler CR; Mishriky BM; Egede LE
Postgrad Med; 2019 Aug; 131(6):376-382. PubMed ID: 31311382
[No Abstract] [Full Text] [Related]
28. A multimarker risk stratification approach to non-ST elevation acute coronary syndrome: implications of troponin T, CRP, NT pro-BNP and fibrin D-dimer levels.
Tello-Montoliu A; Marín F; Roldán V; Mainar L; López MT; Sogorb F; Vicente V; Lip GY
J Intern Med; 2007 Dec; 262(6):651-8. PubMed ID: 17986200
[TBL] [Abstract][Full Text] [Related]
29. Blood pressure and mortality in patients with type 2 diabetes and a recent coronary event in the ELIXA trial.
Wijkman MO; Claggett B; Diaz R; Gerstein HC; Køber L; Lewis E; Maggioni AP; Wolsk E; Aguilar D; Bentley-Lewis R; McMurray JJ; Probstfield J; Riddle M; Tardif JC; Solomon SD; Pfeffer MA
Cardiovasc Diabetol; 2020 Oct; 19(1):175. PubMed ID: 33046070
[TBL] [Abstract][Full Text] [Related]
30. Plasma N-terminal pro-B-type natriuretic peptide and mortality in type 2 diabetes.
Tarnow L; Gall MA; Hansen BV; Hovind P; Parving HH
Diabetologia; 2006 Oct; 49(10):2256-62. PubMed ID: 16937127
[TBL] [Abstract][Full Text] [Related]
31. Predictive value of NT-proBNP for 30-day mortality in patients with non-ST-elevation acute coronary syndromes: a comparison with the GRACE and TIMI risk scores.
Schellings DA; Adiyaman A; Dambrink JE; Gosselink AM; Kedhi E; Roolvink V; Ottervanger JP; Van't Hof AW
Vasc Health Risk Manag; 2016; 12():471-476. PubMed ID: 27920547
[TBL] [Abstract][Full Text] [Related]
32. Relationship and prognostic importance of thyroid hormone and N-terminal pro-B-Type natriuretic peptide for patients after acute coronary syndromes: a longitudinal observational study.
Brozaitiene J; Mickuviene N; Podlipskyte A; Burkauskas J; Bunevicius R
BMC Cardiovasc Disord; 2016 Feb; 16():45. PubMed ID: 26892923
[TBL] [Abstract][Full Text] [Related]
33. Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial.
Zannad F; Cannon CP; Cushman WC; Bakris GL; Menon V; Perez AT; Fleck PR; Mehta CR; Kupfer S; Wilson C; Lam H; White WB;
Lancet; 2015 May; 385(9982):2067-76. PubMed ID: 25765696
[TBL] [Abstract][Full Text] [Related]
34. NT-proANP and NT-proBNP circulating levels as predictors of cardiovascular outcome following coronary stent implantation.
Niccoli G; Conte M; Marchitti S; Montone RA; Fracassi F; Grippo R; Roberto M; Burzotta F; Trani C; Leone AM; Bianchi F; Di Castro S; Volpe M; Crea F; Rubattu S
Cardiovasc Revasc Med; 2016; 17(3):162-8. PubMed ID: 26987266
[TBL] [Abstract][Full Text] [Related]
35. Insulin resistance and acute coronary syndrome.
Caccamo G; Bonura F; Bonura F; Vitale G; Novo G; Evola S; Evola G; Grisanti MR; Novo S
Atherosclerosis; 2010 Aug; 211(2):672-5. PubMed ID: 20466373
[TBL] [Abstract][Full Text] [Related]
36. Prognostic value of N-terminal-pro-brain natriuretic peptide measurements in patients with acute coronary syndromes.
Ranjith N; Pegoraro RJ; Naidoo DP; Esterhuizen TM
Cardiovasc J S Afr; 2006; 17(2):60-6. PubMed ID: 16733598
[TBL] [Abstract][Full Text] [Related]
37. NT-proBNP is increased in differentiated thyroid carcinoma patients and may predict cardiovascular risk.
Klein Hesselink EN; van der Horst-Schrivers ANA; van der Horst ICC; Bakker SJL; Muller Kobold AC; Brouwers AH; de Bock GH; Gietema JA; Dullaart RPF; Links TP; Lefrandt JD
Clin Biochem; 2017 Aug; 50(12):696-702. PubMed ID: 28242284
[TBL] [Abstract][Full Text] [Related]
38. Pioglitazone Prevents Diabetes in Patients With Insulin Resistance and Cerebrovascular Disease.
Inzucchi SE; Viscoli CM; Young LH; Furie KL; Gorman M; Lovejoy AM; Dagogo-Jack S; Ismail-Beigi F; Korytkowski MT; Pratley RE; Schwartz GG; Kernan WN;
Diabetes Care; 2016 Oct; 39(10):1684-92. PubMed ID: 27465265
[TBL] [Abstract][Full Text] [Related]
39. Additive prognostic value of plasma N-terminal pro-brain natriuretic peptide and coronary artery calcification for cardiovascular events and mortality in asymptomatic patients with type 2 diabetes.
von Scholten BJ; Reinhard H; Hansen TW; Lindhardt M; Petersen CL; Wiinberg N; Hansen PR; Parving HH; Jacobsen PK; Rossing P
Cardiovasc Diabetol; 2015 May; 14():59. PubMed ID: 25990319
[TBL] [Abstract][Full Text] [Related]
40. Early discharge after primary percutaneous coronary intervention: the added value of N-terminal pro-brain natriuretic peptide to the Zwolle Risk Score.
Schellings DA; Adiyaman A; Giannitsis E; Hamm C; Suryapranata H; Ten Berg JM; Hoorntje JC; Van't Hof AW
J Am Heart Assoc; 2014 Nov; 3(6):e001089. PubMed ID: 25389283
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
